key: cord-0895315-0wpzsmoy
authors: Uzelac, Ilija; Iravanian, Shahriar; Ashikaga, Hiroshi; Bhatia, Neal K.; Herndon, Conner; Kaboudian, Abouzar; Gumbart, James C.; Cherry, Elizabeth M.; Fenton, Flavio H.
title: Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19
date: 2020-05-29
journal: Heart Rhythm
DOI: 10.1016/j.hrthm.2020.05.030
sha: f9a3267ad4e87392bf8c72f22a353532dbf28222
doc_id: 895315
cord_uid: 0wpzsmoy

BACKGROUND: Early during the current COVID-19 pandemic, hydroxychloroquine (HCQ) received a significant amount of attention as a potential antiviral treatment, such that it became one of the most commonly prescribed medications for COVID-19 patients. However, not only the effectiveness of HCQ has remained questionable, and mainly based on pre-clinical, and a few small clinical studies, but also HCQ is known to be potentially arrhythmogenic, especially as a result of QT prolongation. OBJECTIVE: To investigate the arrhythmic effects of HCQ as the heightened risk is especially relevant as COVID-19 patients are at a higher risk of cardiac complications and arrhythmias at baseline. METHODS: Here, we use the optical mapping technique, using voltage-sensitive fluorescent dyes, to illustrate the arrhythmic effects of hydroxychloroquine in ex-vivo guinea pig and rabbit hearts perfused with the upper therapeutic serum doses of HCQ (up to 1000ng/ml). RESULTS: We observe that HCQ markedly increases the action potential dispersion and results in the development of repolarization alternans and initiate polymorphic ventricular tachycardia. CONCLUSIONS: These results further highlight the proarrhythmic effects of HCQ.

Background: Early during the current COVID-19 pandemic, hydroxychloroquine (HCQ) received a significant amount of attention as a potential antiviral treatment, such that it became one of the most commonly prescribed medications for COVID-19 patients. However, not only the effectiveness of HCQ has remained questionable, and mainly based on pre-clinical, and a few small clinical studies, but also HCQ is known to be potentially arrhythmogenic, especially as a result of QT prolongation.

Objective: To investigate the arrhythmic effects of HCQ as the heightened risk is especially relevant as COVID-19 patients are at a higher risk of cardiac complications and arrhythmias at baseline.

Methods: Here, we use the optical mapping technique, using voltage-sensitive fluorescent dyes, to illustrate the arrhythmic effects of hydroxychloroquine in ex-vivo guinea pig and rabbit hearts perfused with the upper therapeutic serum doses of HCQ (up to 1000ng/ml).

Results: We observe that HCQ markedly increases the action potential dispersion and results in the development of repolarization alternans and initiate polymorphic ventricular tachycardia.

Conclusions: These results further highlight the proarrhythmic effects of HCQ.

The drugs chloroquine(CQ) and hydroxychloroquine (HCQ), a less toxic derivative of QC, used to treat malaria and autoimmune conditions, have been proposed to have antiviral activity against the severe acute respiratory coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic. Recent in vitro studies 1,2 and a small (36 patients) non-randomized clinical trial from France 3 had promising results, which initiated the trend of using CQ/HCQ to treat COVID-19. However, the integrity of that clinical trial is questioned by the International Society of Antimicrobial Chemotherapy for its unclear inclusion criteria and triage of patients 4 . Although a subsequent smaller randomized clinical trial (30 patients) showed little to no effect 5 , HCQ was shown to significantly reduce the incidence and duration of COVID-19 pneumonia in a larger randomized clinical trial (62 patients) 6 . These studies do not have enough statistical power to unequivocally prove the positive effects of HCQ on COVID-19.

Nevertheless, the urgency of the pandemic has resulted in 1) CQ/HCQ receiving an emergency use authorization by the Food and Drug Administration (FDA) for the treatment of COVID-19, an action that has been criticized by former FDA leaders, and 2) a large call by the World Health Organization (WHO) for rapid large global CQ/HCQ clinical trials.

Although CQ and HCQ are becoming the focus of treating COVID-19, they remain unendorsed by many physicians because of 1) limited clinical outcome data, 2) availability of other potentially more effective antiviral and interleukin inhibitors such as remdesivir and tocilizumab respectively, and 3) potential risk of malignant arrhythmia and sudden cardiac death (SCD) due to QT prolongation 7, 8 . In response to the trend to use CQ/HCQ for COVID-19, the Mayo Clinic 9 and the Heart Rhythm Society COVID-19 Task Force with the American Heart Association 10 , along with other clinicians 11 , all independently called for urgently needed guidance when using HCQ alone and in combination with other drugs regarding arrhythmias.

The most pressing issue is to determine the dosage of CQ/HCQ that is effective, yet safe, in particular, for patients at risk 9-12 of drug-induced long QT syndrome (LQT) and SCD. This is especially important as HCQ is now being used in combination with other antivirals and antibiotics such as ritonavir, lopinavir and azithromycin, all of which are also associated with drug-induced LQT 11 . Recent reports have shown direct myocardial involvement in many COVID-19 patients 13 , presumably due to the abundance of angiotensin-converting enzyme 2 (ACE2) receptors on the cardiac cell surface, which is the main entry point of SARS-CoV-2. Evidence of myocardial damage has been described in the form of elevated troponin and high inflammatory burden that can induce vascular inflammation and myocarditis 13, 14 . Computational models have proposed that the SARS-Cov-2 envelop protein E' forms a pentameric ion channel and it is possible that incorporation of this channel in the cell membrane of cardiac myocytes may contribute to the reported arrhythmic events in COVID-19. Clinically, some patients with severe COVID-19 develop left ventricular dysfunction, cardiogenic shock, and various cardiac arrhythmias 15, 16 . Consequently, many COVID-19 patients are already susceptible to arrhythmias and may be at even higher risk of deadly arrhythmogenic effects with COVID-19 drug combination treatments.

A recent clinical trial in Brazil (81 patients) that tested two different doses of CQ 17 was prematurely halted because several patients in the high dose group developed LQT and experienced malignant arrhythmias, including ventricular tachycardia, within the first three days; subsequently, 11 patients died within six days. While the precise mechanisms by which QC/HCQ initiate arrhythmia remain unclear the electrophysiological effects of HCQ have been investigated in isolated mouse and guinea pig hearts 18 . HCQ primarily blocks the funny current (If), L-type calcium current and rapid delayed rectifier potassium current (IKr). As a result, the main electrophysiological manifestations of HCQ are sinus bradycardia (see supplemental figure) and repolarization abnormalities (QT prolongation, increased repolarization dispersion), which could lead to Torsade de Pointes 19 (TdP) and polymorphic ventricular tachycardia 17 .

Here we illustrate the arrhythmic effects of HCQ using a guinea pig (GP) and a rabbit heart perfused with the upper therapeutic serum dose of 1000ng/ml using optical mapping. For the GP heart, we also used a modified Tyrode's solution for hypokalemia as described in the text.

In the lab, the hearts were immersed in a heated oval chamber kept at (38 ± 0.5 ºC) and Langendorffperfused with Tyrode's solution gassed with a mixture of 95 % O2 / 5 % CO2. Contraction motion was suppressed by (±)-Blebbistatin (Cayman Chemicals) at Tyrode's concentration of 1.5 -2 µM, previously prepared as a stock solution dissolved with DMSO at the ratio of 5 mg/ml. Voltage (Vm)-sensitive dye JPW-6003 (Leslie Loew group, University at Connecticut) was previously prepared as a stock solution dissolved in ethanol at the ratio of 20 mg/ml. We used 0.4 mg of the Vm dye for the whole guinea pig and rabbit hearts. The Vm dye was injected as a bolus in the cannulated aorta over the course of 3 minutes in small injection intervals 15 seconds apart not interfering with the flow rate. The total accommodation time for the heart including dye staining prior to taking initial measurements was 30 minutes. Hydroxychloroquine was added 45 minutes after cannulation into the Tyrode's solution at a concentration of 1000 ng/mL (upper therapeutic dose), previously dissolved in a small Tyrode's solution volume free of organic solvents with 15 minutes of stirring on a hot plate kept at 35 ºC.

Optical mapping setup: Two red LEDs (LED Engin), each 7 W with center wavelength at 660 nm, were used as light sources for the Vm dye excitation, driven from a stabilized current source Plumbus (Pulsed LUMinos Bimodal Uniform Source, donated from Aleksa Tech). LED light was collimated with a plano-convex lens (ThorLabs) and band-pass filtered with 660/10 OD4 filter (Edmund Optics). Emitted florescence was filtered through a 700 nm long-pass OD6 (Chroma Optical) placed on the camera side.

Fluorescence signals were acquired with EMCCD camera (Evolve 128, Photometrics) at a resolution of 128 x 128 pixels, digitized at 16-bits, at 500 FPS and transferred to a PC via real-time uninterrupted data transfer. A custom acquisition program was used for camera control.

Stimulation Protocol: External bipolar stimuli (World Precision Instruments) of 3 -5 ms in duration and with stimulating current twice the pacing threshold of 3 -8 mA were used to investigate the dynamic effect of HCQ. Both before and after HCQ, a down-sweep pacing protocol with pacing cycle length (CLs) starting from 400 ms was applied with the CL gradually shortened in decreasing steps ranging from 5 to 25 ms until conduction block or fibrillationwas reached. For each CL, once steady state conditions were achieved, 20 consecutive beats were recorded. The programming sequence was coordinated with the internal camera trigger clock using an Arduino Uno, which served to control the onset of each pacing stimulus and to synchronize with the camera. This method allowed us to perform image stacking to increase the signal to noise ratio and to avoid using stronger spatio-temporal filtering, which can over smooth signals and leave small beat to beat action potential differences undetected. During alternans, stacking was done separately for even and odd beats. To investigate ectopic beats, we also ran S1-S2 protocols (with S1 of 600ms and 450ms for rabbit and 450ms for GP and with S2 varied down until conduction block, fibrillation or ectopic beat) before and after HCQ.

When fibrillation occurred, defibrillation was performed with low-energy anti-fibrillatory pacing (LEAP) 20 , a low-energy defibrillation method to prevent any tissue damage. For the histograms, APD was calculated at 50% repolarization.

In both preparations, HCQ increased the minimum cycle length (CL) at which it was possible to pace the hearts --that is, as the wavelength increased due to the drug effects, conduction block was easier to elicit at longer periods with the drug, thereby predisposing the heart to arrhythmia. In fact, in the guinea pig and rabbit, no fibrillation was obtained without the drug, and it was possible to pace with no arrhythmias at CLs as short as 130ms for the GP heart and 140ms for the rabbit (see Movie1); shorter CLs led to conduction block but no arrhythmias. In contrast, tachycardia/fibrillation not only appeared in both hearts under the effect of HCQ, but it was inducible at longer CLs. Furthermore, marked alternans in action potential duration (APD) also developed under HCQ. While APD alternans with variations larger than 5ms from beat to beat can be induced in rabbit ventricles, it is only possible at CLs below around 220ms; in GP, alternans is not commonly observed, but when it is, its appears at CLs below 160ms. Under HCQ, APD alternans readily developed at CLs below 380 ms in rabbit and 350ms in GP.

Arrhythmias appeared in the rabbit with HCQ at CLs below 250ms. Figure 1a and Movie 2 show the initiation of fibrillation (multiple waves) by conduction block. Figure 2a For the GP case, we also observed that under HCQ APD dispersion increased, resulting in conduction blocks and arrhythmias initiated below CLs of 220 ms. Figure 2b shows the dispersion of APD at this CL without HCQ and the development of alternans with HCQ. Under HCQ, alternans changed the normal APD min of 80ms and APD max of 120ms to 70ms and 145ms respectively on alternating beats.

The mean APD also changed, alternating between 96ms and 112ms every other beat, thus representing a decrease and increase in the short and long APDs, respectively, compared to the mean APD of 104ms without the drug. Figure 2b also shows the voltage trace and the increase in AP duration and alternans by HCQ.

We observed that although there was a large dispersion of APD across the GP heart, spatial alternans mostly developed as concordant alternans, as shown in figure 3 , where APD alternates from long to short values from beat to beat. Only a small region of the tissue experienced discordant alternans.

However, in rabbit, although the tissue showed a similar range of APDs across the tissue, a more complex spatial pattern developed as alternans was discordant, with some regions of the tissue alternating with long-short APDs and others alternating short-long. The large beat-to-beat changes in APD dispersion due to discordant alternans can be seen in the APD maps and ∆APD maps in figure 3.

While we did not observe ectopic beats in the rabbit heart, we observed ectopic beats in the guinea pig hearts. Figure 1b and Movie 5 show two ectopic beats generated following three stimulations in the guinea pig heart. Movie 6 shows an episode of initiation of VT in the rabbit heart.

As hypokalemia has been shown to be prevalent in Covid-19 patients, we further tested the effect of HCQ under hypokalemia by switching the Tyrode's solution in the GP experiment from normal to one with lower potassium (from 4 to 2.5 mmol/L) and magnesium (from 1 to 0.8 mmol/L). We perfused with hypokalemia Tyrode's solution twice, with normal Tyrode's solution (washout) in between. In both instances, fibrillation spontaneously occurred under the hypokalemic conditions (the heart was defibrillated when back in normal Tyrode's solution), highlighting a possible higher risk of HCQ in patients with hypokalemia and thus the importance of monitoring and treating low potassium levels as they can increase the probability of arrhythmic events 19 .

These experiments show that as the QT interval/APD increased under HCQ, it was possible to induce arrhythmias at CLs closer to the physiological heart rates, demonstrating potential dangers of HCQ. In particular, we observed immediate arrhythmia initiation when hypokalemia was induced with HCQ, but not only in the hypokalemia case. This is important because there is particular concern about hypokalemia in COVID-19 disease 21 , as it seems to be present in almost all Covid-19 patients 22 , likely due to the interaction of SARS-CoV2 with the renin-angiotensin system (RAS), as it binds angiotensin I, converting enzyme 2 of RAS causing prevalent hypokalemia.

With HCQ alone, we observed spatial alternans at longer CLs, including those of normal sinus heart rates without the drug, and while HCQ produces bradycardia that in principle may not allow these CLs to be reachable, sympathetic surges can easily lead to sudden increased heart rates inducing pause/bradycardia arrhythmias such as TdP. Furthermore, The increased APD heterogeneity induced by HCQ at bradycardic cycle lengths also showed dramatic anisotropic conduction slowing even before alternans developed. This phenomenon can be seen clearly in movie 3, where at a cycle length of 380ms a marked slowing in conduction velocity is observed in a region of the heart that produces a non-smooth propagation compared to the case without HCQ at a very short CL of 140ms. HCQ thus induced complex repolarization heterogeneities and a substrate for arrythmias such as TdP.

Our study contains several limitations. The most important is the low number of experiments for rabbit and GP; we are aware that our results are thus more descriptive because statistical analysis cannot be performed. However, as our results in normal rabbit and guinea pig hearts compare well with other studies in both species 23, 24 , and in general when healthy they do not go into fibrillation when slowly paced down (until conduction block), but did under HCQ, we believe that our study has provided some mechanistic insights. Nevertheless, this study needs to be extend to allow for a complete statistical analysis that can solidify the proarrythmic mechanisms of HCQ as well as the possibility of any differences related to sex, as being female is known to be an independent risk factor for developing TdP.

Another limitation of our study is the use of animal models with small hearts and electrophysiology different from human hearts. A major problem with using small hearts is the difficulty of inducing reentrant tachycardias due to the size mismatch between ventricles and reentry wavelength. Therefore, a negative result in small hearts is not reassuring for the absence of arrhythmogenicity in humans.

However, we observed polymorphic VT with characteristics similar to clinical TdP, which is a concerning finding, as it typically is easier to induce TdP in humans than in these models.

The most important ion channels in the genesis of TdP are the delayed-rectifier potassium channels, especially IKr. Both rabbit and GP ventricles have dofetilide-sensitive IKr and are prone to exhibiting repolarization alternans as a result of potassium channel blockade [25] [26] [27] , so that these species are commonly used to test for drug-induced repolarization abnormalities 28,29 that could affect humans.

A challenging aspect of COVID-19 treatment with respect to heart problems is the use of unusual drug combinations, such as HCQ with antibiotics like azithromycin, which prior to the COVID-19 pandemic were rarely used together. While the risk profile of individual drugs on QT prolongation has been characterized, the data on combinations of those drugs are lacking, with just a few studies starting to be available 30 B) Example of arrhythmic ectopic beats following a protocol of two S1 stimuli and a second shorter S2 originating from the apex. Top: voltage signal showing the first two beats from a stimulation protocol that emulates a quick change of rate, which creates two arrhythmic ectopic (premature P1 and P2) beats. Bottom: optical images showing the initiation of the S2 beat at the apex and then the initiation of the first ectopic beat originating from the top center. Color bar indicates tissue polarized (-80mV) in blue and depolarized (+20mV) in red. Fig. 2 . Dispersion of APD due to HCQ in rabbit and guinea pig hearts. Histograms were obtained from optical mapping after steady state was reached for a constant CL of 250ms for the rabbit and 220ms for the GP with and without HCQ. As alternans appeared under HCQ, two histograms are shown, one for even and one for odd beats. A) APD distribution in the rabbit ventricles with normal Tyrode's solution and with HCQ showing an increase in APDmax and alternans from beat to beat. Optical action potentials also illustrate APDmax increase and alternans in duration. B) APD distribution in the GP ventricles with normal Tyrode's solution and with HCQ and optical mapping signal showing similar effect as in the rabbit. Fig. 3 . Spatial dispersion of APD due to HCQ in rabbit and guinea pig hearts. Maps were obtained from steady state activations at a pacing CL of 220ms for GP and 250ms for rabbit. Top row shows the distribution of APD for even and odd beats. Bottom row displays the change in APD (∆APD) for even and odd beats. A) GP displays mostly concordant alternans where most of the tissue experiences a short action potential followed by a long action potential. Only a small region of discordant alternans (DA) with the opposite pattern (long-short) appears by the lower right corner and edges of the tissue. B) Rabbit displays marked DA with different distribution of long and short APD on alternating beats. Note that during DA regions that have a long APD will have a short APD on the next beat and vice versa. Black shows the location of the stimulus electrode; data underneath could not be collected.

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Statement on IJAA paper | International Society of Antimicrobial Chemotherapy

Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ) -Full Text View -ClinicalTrials

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know

COVID-19 Global Rheumatology Alliance †. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19

Urgent guidance, approach to identify patients at risk of drug-induced sudden cardiac death from use of off-label COVID-19 treatments

Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart Rhythm Society COVID-19 Task Force

Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology

SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm

Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)

Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential. Heart rhythm

Chloroquine-induced torsade de pointes in a COVID-19 patient. Heart Rhythm

Synchronization as a mechanism for low-energy anti-fibrillation pacing. Heart rhythm

Cardiac Manifestations Of Coronavirus (COVID-19). InStatPearls online

Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19)

Optical mapping reveals that repolarization spreads anisotropically and is guided by fiber orientation in guinea pig hearts. Circulation research

Simultaneous quantification of spatially discordant alternans in voltage and intracellular calcium in langendorff-perfused rabbit hearts and inconsistencies with models of cardiac action potentials and ca transients. Frontiers in physiology

Dofetilide promotes repolarization abnormalities in perfused guinea-pig heart. Cardiovascular drugs and therapy

Quinidine elicits proarrhythmic changes in ventricular repolarization and refractoriness in guinea-pig

diabetic rabbits: a role of rapid delayed rectifier K+ current

Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval

Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts

The Effect of Chloroquine